APA (7th ed.) Citation

S, J., A, N., Y, M., M, D., L, Z., C, K., . . . JS, W. (2024). AML-VAC-XS15-01: Protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients. Frontiers in oncology, 14, 1458449. https://doi.org/10.3389/fonc.2024.1458449

Chicago Style (17th ed.) Citation

S, Jung, et al. "AML-VAC-XS15-01: Protocol of a First-in-human Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Multi-peptide Vaccine Based on Leukemia Stem Cell Antigens in Acute Myeloid Leukemia Patients." Frontiers in Oncology 14 (2024): 1458449. https://doi.org/10.3389/fonc.2024.1458449.

MLA (9th ed.) Citation

S, Jung, et al. "AML-VAC-XS15-01: Protocol of a First-in-human Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Multi-peptide Vaccine Based on Leukemia Stem Cell Antigens in Acute Myeloid Leukemia Patients." Frontiers in Oncology, vol. 14, 2024, p. 1458449, https://doi.org/10.3389/fonc.2024.1458449.